The tirzepatide formula: what its molecular structure actually does

What the SURMOUNT trial data revealed about tirzepatide's dual mechanism

When Eli Lilly submitted tirzepatide for regulatory review, the evidence base was unusually strong. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and without type 2 diabetes to either tirzepatide or placebo over 72 weeks. At the 15 mg dose, participants lost an average of around 20–21% of their body weight. The 10 mg and 7.5 mg arms also produced meaningful reductions, giving prescribers a graduated picture of what the formula delivers across the dose range.

NICE drew on this data directly when it recommended tirzepatide for use in the UK (TA1026, published December 2024, updated September 2025). The committee found the evidence compelling partly because the results reflected something specific to tirzepatide's formula: activating the GIP receptor alongside GLP-1 appears to produce greater appetite suppression and metabolic benefit than either pathway alone. No other licensed weight-loss medicine in the UK achieves this.

In the SURMOUNT-5 head-to-head trial, published in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks in adults with obesity. The difference matters for anyone comparing options, and it is directly traceable to the structural differences in the two molecules.

The chemistry behind once-weekly dosing: fatty-acid conjugation in the tirzepatide formula

A question our prescribers hear most weeks is why tirzepatide needs only one injection every seven days when the gut hormones it mimics last seconds in the body. The answer sits in the molecule's architecture. Tirzepatide's 39-amino-acid peptide chain is conjugated to a C20 fatty-acid via a linker, a deliberate chemical modification that binds the molecule loosely to albumin proteins in the blood, slowing its clearance and extending its half-life to approximately five to seven days.

This conjugation strategy is described in tirzepatide's prescribing information and distinguishes it from earlier, shorter-acting GLP-1 medicines that required daily injection. You can read the full structural detail in the Mounjaro SmPC on the eMC, which covers the pharmacokinetic properties in plain terms alongside clinical data.

The fatty-acid chain does more than extend duration. It also influences how the molecule distributes through the body and how quickly it reaches steady-state plasma concentrations, which is why tirzepatide treatment starts at 2.5 mg, the starter dose gives your system time to adjust, not because that dose is therapeutic on its own. Each pen contains four weekly doses, all drawn from the same pre-filled KwikPen format.

Understanding the tirzepatide formulation in full (including excipients and storage requirements) is useful if you are considering treatment or transferring from another medicine.

GIP and GLP-1: how tirzepatide's formula engages two separate receptor families

GLP-1 receptor agonists have been used in diabetes and weight management for years. What the tirzepatide chemical formula adds is selective activity at the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is released from the gut after eating and plays a role in fat tissue metabolism and satiety signalling that is separate from (and complementary to) the GLP-1 pathway.

The NHS tirzepatide page notes that the medicine works by acting like these two natural gut hormones, slowing gastric emptying and increasing the feeling of fullness. But the precise balance of GIP-to-GLP-1 activity built into tirzepatide's peptide sequence is what differentiated it in trial design, and what NICE considered when assessing its clinical effectiveness against existing options. You can explore the broader science on the Mounjaro overview page.

It is also worth understanding that the tirzepatide molecular formula represents a fixed structure, the same molecule regardless of the pen strength. The 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg doses reflect concentration, not a change in what the molecule is.

From molecule to medicine: licensing, safety monitoring and what this means for you

Understanding the formula is one thing. Knowing how it translates into a licensed medicine in the UK (and what that licensing process requires) is equally important for anyone researching treatment. The MHRA granted Mounjaro its UK marketing authorisation for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition. It carries a Black Triangle (▼) designation, meaning it is subject to additional monitoring while post-market safety data accumulates. The BNF tirzepatide entry covers the prescribing framework in detail.

The most commonly reported side effects reflect tirzepatide's mechanism directly: nausea, diarrhoea, constipation, indigestion and reduced appetite are all downstream of slowed gastric emptying and altered gut-hormone signalling. These are generally most noticeable when starting treatment or after a dose increase, and often settle within the first couple of weeks.

For people researching what medically supervised weight loss might involve, understanding the formula gives context for why this class of medicine works differently from calorie restriction or older lipase inhibitors. The science is solid. What remains individual is whether tirzepatide is the right fit for you, which is a question for a prescriber, not a search engine. You can also look at the broader tirzepatide formulary context (how it sits within NHS and private commissioning) if access is your main question. For anyone ready to discuss personal suitability, speaking to our prescribers is the straightforward next step.